Last reviewed · How we verify
1278863A
This drug is a small molecule that targets the PI3K delta subunit.
This drug is a small molecule that targets the PI3K delta subunit. Used for Chronic lymphocytic leukemia (CLL), Sjögren's syndrome.
At a glance
| Generic name | 1278863A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the PI3K delta subunit, which is involved in the activation of B cells. This leads to a reduction in the activity of B cells, which are a type of immune cell that plays a key role in the development of autoimmune diseases.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Sjögren's syndrome
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment (PHASE1)
- Repeat Dose Safety Study for Compound to Treat Anemia (PHASE1)
- Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1278863A CI brief — competitive landscape report
- 1278863A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI